Member Info for daveycaferacer

Massive volume today, already over 50% more compared to average and another 3 hours yet in London

so if Milciclib goes into Phase 3 the market will ignore it?

apologies, I meant Nebulizer technology in itself is not part of the patent

I saw that on CNBC. Gilead will know of Nebulizer manufacturers they can use, and we must remember Tiziana have not patented a Nebulizer, which is simply the method of administering the drug or therapy.

A New Trinity Delta Note was released yesterday

https://marketo-web.thousandeyes.com/rs/thousandeyes/images/ThousandEyes-Product-Brief-Platform-Overview.pdf

they don't need codes, they have private messenger services

MIA?

The Company has now added an Expanded Access program to its website, allowing for potential access to drug candidates outside of a clinical trial setting:-

https://www.chi-med.com/innovation-platform/expanded-access/

indeed, and that would suite me fine, the U.S. market is able to correctly value fledgling Biotech based on DCF and other metrics that are well know by the specialist Biotech Investment community, a community that doesn't exist in the UK

New presentations on Surufatinib have been posted

https://www.chi-med.com/news/news-archive/?in=6

One particularly interesting aspect is that treatment related adverse effects were far less in U.S. patients than Chinese patients, which hopefully bodes well for U.S. approval in the future

New York/London - April 27, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it has filed a provisional patent application on the combination of nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor monoclonal antibody (anti-IL-6R) as a potential therapy for management of COVID-19 disease. The underlying invention concepts are based on the hypothesis that a combination of an antiviral drug controlling proliferation of COVID-19, with an anti-inflammatory agent (e.g., anti-IL-6R) suppressing a possible 'Cytokine Storm' may provide immediate relief to severe cases of COVID-19 patients.

In my experience this type of news is rarely discussed at AGM's and there will certainly not be any new news announced at an AGM of a company the size of Sanofi

Another AGM with all resolutions passed, and some interesting questions from some people, most of which were asked at an inappropriate time at the start rather than during Christian's presentation! No questions from me this year, I am just very happy with the substantial progress the Company is making, and hopeful the market will start to value the Company appropriately. Cash position secure until at least the end of 2021 too.

The Americans are coming online, nice rise in pre-market

what "placing at 35p"

It actually says "the exercise of 1,712,672 warrants at a price of 35 pence per share" which is entirely different!

there is nothing "good" about AIM!

Interesting growth numbers Jatw and actually, past mcap CAGR is 29% so anything less is perfectly realistic in my view, although as we have seen, it will be far from linear....

Having been invested in the Company for over 10 years now (first purchase was equivalent to about 20p per share) and still acquiring, I am very happy to be invested for the next 10 years. I agree with Anthony Hilton's assertion from a couple of years ago, this will be a circa $20bn mcap Company at some point in the next decade or so.

I can't see this surviving now

Edison has issued an updated note:-

https://www.edisongroup.com/publication/fortune-favours-the-brave/26645